Nitric oxide donors induce large-scale deletion mutations in human lymphoblastoid cells: Implications for mutations in T-lymphocytes from arthritis patients
Donna D. Grant
Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada
Ottawa Health Research Institute, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Search for more papers by this authorRose Goldstein
Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada
Ottawa Health Research Institute, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Division of Rheumatology, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Search for more papers by this authorJacob Karsh
Division of Rheumatology, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Search for more papers by this authorCorresponding Author
H. Chaim Birnboim
Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada
Ottawa Health Research Institute, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, 503 Smyth Road, Ottawa, Ontario K1H 1C4, CanadaSearch for more papers by this authorDonna D. Grant
Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada
Ottawa Health Research Institute, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Search for more papers by this authorRose Goldstein
Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada
Ottawa Health Research Institute, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Division of Rheumatology, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Search for more papers by this authorJacob Karsh
Division of Rheumatology, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Search for more papers by this authorCorresponding Author
H. Chaim Birnboim
Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ontario, Canada
Ottawa Health Research Institute, Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada
Ottawa Regional Cancer Centre, Centre for Cancer Therapeutics, 503 Smyth Road, Ottawa, Ontario K1H 1C4, CanadaSearch for more papers by this authorAbstract
Rheumatoid arthritis (RA) is an inflammatory disease in which high levels of reactive nitrogen oxygen species (RNOS) may be present in the affected joints. RNOS are known to produce small-scale mutational events (transitions, transversions, small insertions, and small deletions) but the ability of these compounds to cause deletion of large segments of genomic DNA has not been previously determined. To address this question, a human lymphoblastoid cell line (WIL2-NS) was exposed to nitric oxide (NO)–donating drugs and hypoxanthine phosphoribosyltransferase (hprt)–negative clones were selected and analyzed by multiplex-PCR. Large-scale deletions accounted for 60–80% of hprt mutations arising in drug-treated cultures compared to 12% in untreated cultures (P-values of 0.006 and 0.0001, respectively, in two experiments). Deletion mutations in untreated cultures affected exon 9, whereas 75% of drug-induced deletion mutations affected exons 2, 3, and 9, and the remainder were very large, ranging from 26 to 1200 kbp. To compare this spectrum of NO-induced mutations in a lymphoblastoid line to that arising in vivo in arthritis patients, T-cells from RA patients, osteoarthritis (OA) patients, and controls were cloned and similarly analyzed. We previously showed that the overall frequency of Hprt mutant clones from patients is appreciably elevated compared to that of control subjects. Large-scale hprt deletions (0.5 to >26 kb) were detected in mutant T-cell clones from both RA and OA patients and also from control subjects. A total of 54 mutant clones from 16 RA patients and 19 mutant clones from 6 OA patients were studied. Of these, 6 clones (from 3 RA and 1 OA patient) had suffered large-scale deletions. A total of 9 control subjects were studied and 62 mutant clones were obtained. Of these, 19 had suffered large-scale deletions, arising in 7 of 9 control subjects. In conclusion, (1) RNOS are capable of inducing large-scale deletion mutations in a human lymphoblastoid cell line and (2) large-scale deletion mutations were found in 10–30% of T-cell clones from RA and OA patients and controls, which we hypothesize may be induced by RNOS. Environ. Mol. Mutagen. 38:261–267, 2001. © 2001 Wiley-Liss, Inc.
REFERENCES
- Abramson LS, Albertini RJ, Pachman LM, Finette BA. 1999. Association among somatic HPRT mutant frequency, peripheral blood T-lymphocyte clonality, and serologic parameters of disease activity in children with juvenile onset dermatomyositis. Clin Immunol 91: 61–67.
- Albertini RJ, Nicklas JA, Fuscoe JC, Skopek TR, Branda RF, O'Neill JP. 1993. In vivo mutations in human blood cells: biomarkers for molecular epidemiology. Environ Health Perspect 99: 135–141.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324.
- Birnboim HC. 1993. Extraction of high molecular weight RNA and DNA from cultured mammalian cells. Methods Enzymol 216: 154–160.
- Borderie D, Hilliquin P, Hernvann A, Kahan A, Menkes CJ, Ekindjian OG. 1999. Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol 26: 2083–2088.
- Burkhart-Schultz KJ, Jones IM. 1997. Deletion and insertion in vivo somatic mutations in the hypoxanthine phosphoribosyltransferase (hprt) gene of human T-lymphocytes. Environ Mol Mutagen 30: 371–384.
- Burney S, Caulfield JL, Niles JC, Wishnok JS, Tannenbaum SR. 1999. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res 424: 37–49.
- Cannons J, Goldstein R, Karsh J, Birnboim HC. 1998. Hprt-mutant T cells in the peripheral blood and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 41: 1772–1782.
- Choi PM, Zelig MP. 1994. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35: 950–954.
- Dawisha SM, Gmelig-Meyling F, Steinberg AD. 1994. Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus. Arthritis Rheum 37: 270–277.
- Delaney CA, Green IC, Lowe JE, Cunningham JM, Butler AR, Renton L, D'Costa I, Green MH. 1997. Use of the comet assay to investigate possible interactions of nitric oxide and reactive oxygen species in the induction of DNA damage and inhibition of function in an insulin-secreting cell line. Mutat Res 375: 137–146.
- DeRojas-Walker T, Tamir S, Ji H, Wishnok JS, Tannenbaum SR. 1995. Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA. Chem Res Toxicol 8: 473–477.
- Farrell AJ, Blake DR, Palmer RM, Moncada S. 1992. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 51: 1219–1222.
- Fuscoe JC, Zimmerman LJ, Harrington-Brock K, Moore MM. 1992. Large deletions are tolerated at the hprt locus of in vivo derived human T-lymphocytes. Mutat Res 283: 255–262.
- Grabowski PS, England AJ, Dykhuizen R, Copland M, Benjamin N, Reid DM, Ralston SH. 1996. Elevated nitric oxide production in rheumatoid arthritis. Detection using the fasting urinary nitrate:creatinine ratio. Arthritis Rheum 39: 643–647.
- Grabowski PS, Wright PK, Van't Hof RJ, Helfrich MH, Ohshima H, Ralston SH. 1997. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol 36: 651–655.
- Grant DD, Goldstein R, Karsh J, Birnboim HC. 1999. Elimination of non-viable 6-thioguanine-sensitive T cells from viable T cells prior to PCR analysis. J Immunol Methods 225: 61–66.
- Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. 1982. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131–138.
- Hilliquin P, Borderie D, Hernvann A, Menkès CJ, Ekindjian OG. 1997. Nitric oxide as S-nitrosoproteins in rheumatoid arthritis. Arthritis Rheum 40: 1512–1517.
- Hüttner E, Holzapfel B. 1996. HPRT mutant frequencies and detection of large deletions by multiplex-PCR in human lymphocytes of vinyl chloride exposed and non-exposed populations. Toxicol Lett 88: 175–183.
- Keefer LK, Wink DA. 1996. DNA damage and nitric oxide. Adv Exp Med Biol 387: 177–185.
- Laakso M, Mutru O, Isomaki H, Koota K. 1986. Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 13: 522–526.
- Lotz M. 1999. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 25: 269–282.
- Mariette X. 1999. Lymphomas in patients with Sjogren's syndrome: review of the literature and physiopathologic hypothesis. Leuk Lymphoma 33: 93–99.
- McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, Mumford R, Liew FY. 1996. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 184: 1519–1524.
- Miyasaka N, Hirata Y. 1997. Nitric oxide and inflammatory arthritides. Life Sci 61: 2073–2081.
- Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H. 1997. Nitric oxide as a carcinogen: analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 379: 211–218.
- Murrell GAC, Dolan MM, Jang D, Szabo C, Warren RF, Hannafin JA. 1996. Nitric oxide: an important articular free radical. J Bone Joint Surg Am 78A: 265–274.
- Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. 1992. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 89: 3030–3034.
- Ohshima H, Bartsch H. 1994. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res Fundam Mol Mech Mutagen 305: 253–264.
- Perkins DJ, St. Clair EW, Misukonis MA, Weinberg JB. 1998. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 41: 2205–2210.
- Sakurai H, Kohsaka H, Liu MF, Higashiyama H, Hirata Y, Kanno K, Saito I, Miyasaka N. 1995. Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest 96: 2357–2363.
- Sandhu JK, Birnboim HC. 1997. Mutagenicity and cytotoxicity of reactive oxygen and nitrogen species in the MN-11 murine tumor cell line. Mutat Res 379: 241–252.
- Sfikakis PP, Tesar J, Theocharis S, Klipple GL, Tsokos GC. 1994. Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis. Ann Rheum Dis 53: 122–127.
- Smith KJ, Kapoor R, Felts PA. 1999. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9: 69–92.
- Sriram S. 1994. Longitudinal study of frequency of HPRT mutant T cells in patients with multiple sclerosis. Neurology 44: 311–315.
- Stichtenoth DO, Fauler J, Zeidler H, Frolich JC. 1995. Urinary nitrate excretion is increased in patients with rheumatoid arthritis and reduced by prednisolone. Ann Rheum Dis 54: 820–824.
- Szabó C, Ohshima H. 1997. DNA damage induced by peroxynitrite: subsequent biological effects. Nitric Oxide 1: 373–385.
- Theocharis S, Sfikakis PP, Lipnick RN, Klipple GL, Steinberg AD, Tsokos GC. 1995. Characterization of in vivo mutated T cell clones from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 74: 135–142.
- Van den Berg LH, Mollee I, Wokke JHJ, Logtenberg T. 1995. Increased frequencies of HPRT mutant T-lymphocytes in patients with Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 58: 37–42.
- Wigand R, Meyer J, Busse R, Hecker M. 1997. Increased serum NG-hydroxy-L-arginine in patients with rheumatoid arthritis and systemic lupus erythematosus as an index of an increased nitric oxide synthase activity. Ann Rheum Dis 56: 330–332.
- Wilkinson D, Sandhu JK, Breneman JW, Tucker JD, Birnboim HC. 1995. Hprt mutants in a transplantable murine tumour arise more frequently in vivo than in vitro. Br J Cancer 72: 1234–1240.
- Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. 1998. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19: 711–721.
- Wiseman H, Halliwell B. 1996. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313(Pt 1): 17–29.
- Yermilov V, Rubio J, Ohshima H. 1995. Formation of 8-nitroguanine in DNA treated with peroxynitrite in vitro and its rapid removal from DNA by depurination. FEBS Lett 376: 207–210.
- Zhuang JC, Lin C, Lin D, Wogan GN. 1998. Mutagenesis associated with nitric oxide production in macrophages. Proc Natl Acad Sci USA 95: 8286–8291.
- Zhuang JC, Wright TL, DeRojas-Walker T, Tannenbaum SR, Wogan GN. 2000. Nitric oxide-induced mutations in the hprt gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium. Environ Mol Mutagen 35: 39–47.